These smaller, binary complexes and the higher amount of free big IGF-II contribute to greater bioavailability, leading to fasting hypoglycemia by suppressing hepatic gluconeogenesis and glycogenolysis, increasing skeletal muscle and adipose tissue glucose uptake, and decreasing lipolysis [42,44]. This evidence concerns the gene IGF2 and Hypoglycemia.